ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs

Author： Vautier Sarah   Fernandez Christine  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.5, Iss.11, 2009-11, pp. : 1349-1358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 6, 2012-09 ,pp. : 768-773

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2

By Lepper Erin R   Nooter Kees   Verweij Jaap   Acharya Milin R   Figg William D   Sparreboom Alex  

Pharmacogenomics, Vol. 6, Iss. 2, 2005-03 ,pp. : 115-138

Future Medicine

Access to resources Recommend Favorite

Lamotrigine has no antiparkinsonian activity in rat models of Parkinson's disease

By Loschmann P.-A.   Eblen F.   Wullner U.   Wachtel H.   Klockgether T.  

European Journal of Pharmacology, Vol. 284, Iss. 1, 1995-09 ,pp. : 129-134

Elsevier

Access to resources Recommend Favorite

Emerging analgesic drugs for Parkinson's disease

By Perez-Lloret Santiago   Rey María Verónica   Dellapina Estelle   Pellaprat Jean   Brefel-Courbon Christine   Rascol Olivier  

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 157-171

Informa Healthcare

Access to resources Recommend Favorite

The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinson's Disease

By  

Current Clinical Pharmacology, Vol. 2, Iss. 3, 2007-01 ,pp. : 234-243

Bentham Science Publishers

Access to resources Recommend Favorite